On November 16, 2021, Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle (EV) non-viral delivery technology to develop transformative therapeutics, will be featured at the 3rd Exosome-Based Therapeutic Development Summit occurring November 16-18, 2021, in a presentation led by Vesigen’s Chief Scientific Officer, Joseph Nabhan, PhD. Showcasing the reunion of leading pharma, biotech, technology providers, and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine, autoimmunity, COVID-19, and beyond, the 3rd Exosome-Based Therapeutic Development Summit is an exciting opportunity that marks Vesigen’s first presentation event at an industry-dedicated meeting. The Vesigen presentation highlights new data announced earlier this year on ARMMs [arrestin domain containing protein 1 (ARRDC1)-mediated microvesicles] payloading, purification, and characterization, including demonstration of cellular uptake and intracellular cargo activity. These results illustrate the ability of Vesigen’s proprietary platform to produce ARMMs in a scalable process and effectively deliver functional payloads.